Safety and efficacy of transurethral holmium laser enucleation of the prostate versus bipolar transurethral resection of the prostate in the treatment of benign prostatic hyperplasia: a prospective randomized controlled trial
Langenbeck's Archives of Surgery · 2024
DOI: 10.1007/s00423-024-03499-2 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Langenbeck's Archives of Surgery, 2024. Verfasst von Bin Jiang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Haiyan People's Hospital, Haiyan, Zhejiang, 314300, China. Hauptthemen laut MEDLINE: Prostatic Hyperplasia, Lasers, Solid-State, Transurethral Resection of Prostate. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 53 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: To evaluate the safety and efficacy of transurethral holmium laser enucleation of the prostate (HoLEP) compared to bipolar transurethral resection of the prostate (bTUR-P) in the treatment of benign prostatic hyperplasia (BPH). METHODS: A total of 220 BPH patients hospitalized from January 2022 to September 2023 were included in this study. These patients were randomly assigned to HoLEP and bTUR-P groups, with 110 participants in each group. We collected preoperative general information, perioperative data, complications, and postoperative follow-up indicators from both groups of patients. RESULTS: The baseline characteristics of patients in both groups were similar, with no statistical significance (P > 0.05). Compared to the bTUR-P group, the HoLEP group exhibited significantly less intraoperative bleeding (P < 0.001), shorter bladder irrigation time (P = 0.002), shorter catheter retention time (P < 0.001), and reduced postoperative hospitalization (P = 0.002). Additionally, the pain score during urination after catheter removal was significantly lower in the HoLEP group (P < 0.001). Postoperative complications occurred in both groups; however, they were less frequent in the HoLEP group (4 cases), primarily consisting of urinary retention and postoperative bleeding. The bTUR-P group experienced more complications (9 cases). Significant reductions in postoperative residual urine volume (RUV) were observed in both groups (P < 0.001). Both groups also showed significant improvements in Quality of Life (QoL) scores and International Prostate Symptom Scores (IPSS), with the HoLEP group demonstrating a more significant decrease in IPSS (P < 0.001). CONCLUSION: After comprehensive evaluation, HoLEP was superior to bTUR-P in terms of safety and efficacy. Therefore, HoLEP may be a preferable choice for the treatment of BPH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Haiyan People's Hospital, Haiyan, Zhejiang, 314300, China.
- The Yangtze River Delta Biological Medicine Research and Development Center of Zhejiang Province, Yangtze Delta Region Institution of Tsinghua University, Hangzhou, Zhejiang, 314006, China.
- Department of Urology, Haiyan People's Hospital, Haiyan, Zhejiang, 314300, China. slpabcd@outlook.com.
Zitieren
APA
Jiang, B., Liang, P., Wu, Y., Wang, W., & Shen, L. (2024). Safety and efficacy of transurethral holmium laser enucleation of the prostate versus bipolar transurethral resection of the prostate in the treatment of benign prostatic hyperplasia: a prospective randomized controlled trial. Langenbeck's Archives of Surgery. https://doi.org/10.1007/s00423-024-03499-2
Vancouver
Jiang B, Liang P, Wu Y, Wang W, Shen L. Safety and efficacy of transurethral holmium laser enucleation of the prostate versus bipolar transurethral resection of the prostate in the treatment of benign prostatic hyperplasia: a prospective randomized controlled trial. Langenbeck's Archives of Surgery. 2024. doi:10.1007/s00423-024-03499-2
BibTeX
@article{Jiang2024,
author = {Jiang, Bin and Liang, Ping and Wu, Yanlei and Wang, Wenmin and Shen, Liping},
title = {Safety and efficacy of transurethral holmium laser enucleation of the prostate versus bipolar transurethral resection of the prostate in the treatment of benign prostatic hyperplasia: a prospective randomized controlled trial},
journal = {Langenbeck's Archives of Surgery},
year = {2024},
doi = {10.1007/s00423-024-03499-2}
}
EUVIMED